
First Patient Dosed in Trial of CT-95 in Mesothelin-Expressing Tumors
The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors. The development was announced in a news release issued by biopharmaceutical company Context Therapeutics Inc. CT-95 is a …